Exchange: NASDAQ·Updated 07:48 PM EST

BEAT News

News
all
press releases
HeartBeam, Inc. 2026 Q3 - Results - Earnings Call Presentation
HeartBeam, Inc. 2026 Q3 - Results - Earnings Call Presentation...
SeekingAlpha
HeartBeam, Inc. 2026 Q3 - Results - Earnings Call Presentation
HeartBeam, Inc. 2026 Q3 - Results - Earnings Call Presentation...
SeekingAlpha
More News
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today reported its financial and operational results for the third quarter ended September 30, 2026. Third Quarter & Subsequent 2026 Operational Highlights...
Business Wire
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, will hold a conference call on Thursday, November 12, 2026 at 4:30 p.m. Eastern time to discuss its results for the third quarter ended September 30, 2026...
Business Wire
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming the detection and monitoring of critical cardiac conditions, today announced positive results from its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack assessment. The results were presented...
Business Wire
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that the results of the ALIGN-ACS pilot study evaluating the HeartBeam 3D ECG technology for heart attack assessment will be presented at TCT...
Business Wire
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that the U.S. Food and Drug Administration (FDA) has accepted the HeartBeam System into its Total Product Life Cycle Advisory Program (TAP...
Business Wire
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that the HEADSTART-ACS study, conducted at the National Cardiovascular Center Harapan Kita in Jakarta, Indonesia, has completed enrollment ahead...
Business Wire
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced it is a contributing partner in the launch of the EXIT-CVD research project, co-funded by the European Union Innovative Health Initiative (IHI...
Business Wire
Gainers HeartBeam (NASDAQ:BEAT) stock moved upwards by 70.5% to $0.74 during Monday's regular session. The market value of their outstanding shares is at $24.4 million. PDS Biotechnology (NASDAQ:PDSB) shares movedread more...
Benzinga
HeartBeam (NASDAQ:BEAT) scored a significant regulatory catalyst as the U.S. FDA granted Breakthrough Device Designation to the HeartBeam System for its potential use in assessing suspected heart attacks outside the hospital. The designation gives the company prioritized interaction with the FDA as it works toward a pivotal study and potential expansion of the device’s indication.
24-7 Market News

Advertisement|Remove ads.